Company intelligence / Profile preview

neuro42

San Francisco, California, United Statesneuro42.ai ↗

Ownership: Private
Development stage: Commercial

Overview

neuro42 has received FDA 510(k) clearance for its portable diagnostic MRI scanner. The company is preparing for commercial launch in 2024. Its technology enables point-of-care brain imaging and live image-guided interventions with a focus on improving accessibility and outcomes in neurological care. Clinical scans are ongoing to further validate the system’s utility in real-world settings

Therapeutic areas: Neurology
Modalities: DeviceArtificial intelligence (AI)Robotics platform
Industry: Medical Imaging

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on neuro42.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on neuro42.

Explore the full profile